• <em>Neisseria meningitidis</em> with decreased susceptibility to penicillin G and molecular characterization of the penA gene in strains isolated at University Hospital Centers of Casablanca and Marrakech (Morocco)
• 4CMenB journey to the 10-year anniversary and beyond
• 4CMenB Vaccination to Prevent Meningococcal B Disease in Vietnam: Expert Review and Opinion
• A Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C
• A National Advisory Committee on Immunization (NACI) update on invasive meningococcal disease (IMD) epidemiology and program-relevant considerations for preventing IMD in individuals at high risk of exposure
• An isothermal CRISPR- based lateral flow assay for detection of Neisseria meningitidis
• An Outbreak of Serogroup Y Meningococcal Meningitis in a Private Secondary Vocational School - Guangzhou City, Guangdong Province, China, 2023
• Analysis of adult vaccination in Shandong Province from 2018 to 2022
• Analysis of meningococcal vaccine uptake in patients with invasive meningococcal disease, Czech Republic, 2006-2022
• Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations
• Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report
• Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals
• Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial
• Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy
• Cases of Meningococcal Disease Associated with Travel to Saudi Arabia for Umrah Pilgrimage - United States, United Kingdom, and France, 2024
• CDC guidance on new pentavalent meningococcal vaccine
• CDC Warns of Surge in Meningococcal Disease in US
• Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine
• Community-Acquired Bacterial Meningoencephalitis: The New Guideline
• Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol
• Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021-2022
• Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China
• Determine the factors affecting the time to recovery of children with bacterial meningitis at Jigjiga university referral hospital in the Somali Regional State of Ethiopia: using the parametric shared frailty and AFT models
• Developing a Novel Murine Meningococcal Meningitis Model Using a Capsule-Null Bacterial Strain
• Diverse proinflammatory response in pharyngeal epithelial cells upon interaction with Neisseria meningitidis carriage and invasive isolates
• Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 2 factorial design
• Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review
• Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study
• Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England
• Emerging Meningococcal B Meningitis in Japan: A Case Report of a 50-Year-Old Japanese Man with Diabetes
• Epitope Mapping of Human Polyclonal Antibodies to the fHbp Antigen of a Neisseria Meningitidis Vaccine by Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS)
• Exploring meningococcal serogroup B vaccination conversations under shared clinical decision-making in the US
• Fever and Rash
• Five-in-One Meningitis Vaccine Rolls Out
• Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014
• Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018
• Geographical distribution of invasive meningococcal disease and carriage: A spatial analysis
• HPV Vaccine Awareness, Past Behaviors, and Future Intentions Among a Diverse Sample of Fathers Aged 27 to 45 Years: A National Survey
• HPV vaccine behaviors and intentions among a diverse sample of women aged 27-45 years: implications for shared clinical decision-making
• Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines
• Hybrid response to SARS-CoV-2 and <em>Neisseria meningitidis</em> C after an OMV-adjuvanted immunization in mice and their offspring
• Immune interface interference vaccines: An evolution-informed approach to anti-bacterial vaccine design
• Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
• Impact of Meningococcal ACWY Vaccination Program during 2017-18 Epidemic, Western Australia, Australia
• Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain
• Increased Risk of Long-Term Disabilities Following Childhood Bacterial Meningitis in Sweden
• Interaction of <em>Neisseria meningitidis</em> carrier and disease isolates of MenB cc32 and MenW cc22 with epithelial cells of the nasopharyngeal barrier
• Invasive meningococcal disease in older adults: current perspectives and call for action
• Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study
• Investigation and response to an outbreak of Neisseria meningitidis serogroup Y ST-1466 urogenital infections, Australia
• Investigation of a bacterial meningitis cluster in a refugee settlement, Obongi District, Uganda, March 2023
• Lessons of the month 2: Meningococcal epiglottitis and connective tissue disease associated with C2 deficiency
• Limb Ischemic Necrosis Secondary to Microvascular Thrombosis: A Brief Historical Review
• Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
• Longitudinal study of meningococcal carriage in adolescents and young adults in South Australia 2017-2020
• Meningococcal Disease in Persons With HIV Reported Through Active Surveillance in the United States, 2009-2019
• Meningococcal meningitis in Chile between 1990 and 2019
• Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2023
• Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2023
• Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2023
• Mpox in children and adolescents and contact follow-up in school settings in greater Paris, France, May 2022 to July 2023
• Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol
• Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C
• Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion
• New Prevention Guidance for Antibiotic-Resistant Meningococcal Cases
• News Brief: Invasive meningococcal disease is on the rise in the United States
• Nigeria leads pentavalent meningitis vaccine rollout
• Nigeria rolls out novel meningitis vaccine
• Not Only Meningitis but Also Epiglottitis: An Emerging Clinical Presentation of Invasive Meningococcal Disease
• Novel Pathogenic C5 Gene Variants in a Patient with Neisseria Meningitis and Diffuse Cutaneous HSV-1 Infection
• Nurses' preferences regarding MenACWY conjugate vaccines attributes: a discrete choice experiment in Spain
• Obstetric and Neonatal Invasive Meningococcal Disease Caused by Neisseria meningitidis Serogroup W, Western Australia, Australia
• On The Horizon: Novel Approaches to Sexually Transmitted Infection Prevention
• Out-of-hours General Practice: a case-report about Neisseria meningitidis in the health district of Grado (Gorizia), Italy.
• Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
• Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
• Positive effects of health behaviors acquired during the COVID-19 pandemic process on the prevention of other infectious diseases
• Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study
• Prevalence and persistence of Neisseria meningitidis carriage in Swedish university students - CORRIGENDUM
• Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary
• Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review
• Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
• Recent increase in atypical presentations of invasive meningococcal disease in France
• Respiratory syncytial virus: Time for surveillance across all ages, with a focus on adults
• Routine and Special Vaccinations in People With HIV
• Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
• Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - United States, 2024
• Serogroup B Invasive Meningococcal Disease in Older Adults Identified by Genomic Surveillance, England, 2022-2023
• Severe Meningococcal Meningitis Revealing a Novel Form of Properdin Deficiency in a Previously Healthy 13-year-old Child
• Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
• Sweet complexity: <em>O</em>-linked protein glycosylation in pathogenic <em>Neisseria</em>
• Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex
• The impact of regional disparities on the availability of meningococcal vaccines in the US
• The important lessons lurking in the history of meningococcal epidemiology
• Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings
• Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged 10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
• Vaccination may be economically and epidemiologically advantageous over frequent screening for gonorrhea prevention
• Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis
• Waterhouse-Friderichsen syndrome, septic adrenal apoplexy
• WHO Strategic Advisory Group of Experts on Immunization recommendations for use of a novel pentavalent meningococcal ACWXY vaccine: a critical step towards ending meningococcal epidemics in Africa